Search Results 101-110 of 20718 for colitis

  1. Induction Therapy With RO7790121 in Patients With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

    ... colitis (UC). RO7790121 is a fully human immunoglobulin G1 monoclonal ... colitis, infectious colitis, radiation colitis, or active diverticular disease.

  2. Mesalamine (oral route) - Mayo Clinic

    For the treatment of ulcerative colitis: For long-acting oral dosage form (delayed-release capsules):. Adults—800 milligrams (mg) 3 times a day.

  3. Evaluation of the Relationship Between Pouch Function and Pouch Inflammation in Patients with Ulcerative Colitis - Mayo Clinic

    Confirmed diagnosis of ulcerative colitis (UC) and a history of total abdominal colectomy (TAC) with ileal pouch anal anastomosis (IPAA); Closure of ...

  4. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    ... colitis (UC) who are refractory to or intolerant of TNF inhibitors. Participation eligibility. Participant eligibility includes age, gender, type and stage ...

  5. A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis - Mayo Clinic

    The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis ( ...

  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    ... Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab Title ...

  7. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    This study is designed to evaluate the efficacy and safety of tofacitinib (CP-690,550) in patients with moderate to severe ulcerative colitis who have failed or ...

  8. Mesalamine (rectal route) - Side effects & dosage - Mayo Clinic

    Mesalamineenema is used to treat active mild to moderate ulcerative colitis, proctitis or proctosigmoiditis (inflammation of the rectum and bowel). It works ...

  9. Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies - Mayo Clinic

    ... colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the Phase II ...

  10. Lifestyle and Diet in Inflammatory Bowel Disease - Mayo Clinic News Network

    Inflammatory bowel disease (IBD), which consists of Crohn's disease and ulcerative colitis, can be a frustrating diagnosis to deal with. In general, there ...